Researchers investigating the efficacy and tolerability of atypical antipsychotics in the long-term treatment of schizophrenia found that Pfizer's ziprasidone (Geodon) in twice-daily or 4-times-a-day dosing effectively achieves remission and encourages maintenance. In a double- blind, randomized, 40-week continuation study, 72 participants with schizophrenia received 40 to 80 mg of ziprasidone bid; another group of 67 patients received 80 to 120 mg of ziprasidone qd; and a third group of 47 received 5 to 20 mg/d of haloperidol. Efficacy was defined by maintenance over a 6-month period and a simultaneous rating of <3 ("mild") on all Positive and Negative Syndrome Scale remission criteria. Researchers also used their own observations at each week's follow-up to make an assessment. Baseline severity was comparable for all treatment groups. Discontinuation rates (up to 4 years) were 65% and 58%, respectively, for the ziprasidone groups (bid and qd) and 66% for the haloperidol group. Achievement of at least one symptomatic remission was 57% for both ziprasidone groups and 45% for the haloperidol group. In the study's final 6 months, a greater percentage of patients was experiencing remission in the ziprasidone groups than in the haloperidol group: 41% and 43%, compared with 23%. These results support the effectiveness of ziprasidone in both dose regimens for the long-term treatment of patients with schizophrenia, because both observed response and clinical remission rates were higher than those of haloperidol.
Ms. Farley is a freelance medical writer based in Wakefield, RI.
5 Studies That Shaped HIV Treatment That Every Pharmacist Should Know
Over the years, a number of landmark clinical studies in the field of virology have been published, shaping how we treat many infectious diseases today.
News from the year's biggest meetings
Clinical features with downloadable PDFs